Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 771

1.

Peculiarities of L: -DOPA treatment of Parkinson's disease.

Kostrzewa RM, Nowak P, Kostrzewa JP, Kostrzewa RA, Brus R.

Amino Acids. 2005 Mar;28(2):157-64. Epub 2005 Mar 9. Review.

PMID:
15750845
2.
3.

TRK-820, a selective kappa opioid receptor agonist, could effectively ameliorate L-DOPA-induced dyskinesia symptoms in a rat model of Parkinson's disease.

Ikeda K, Yoshikawa S, Kurokawa T, Yuzawa N, Nakao K, Mochizuki H.

Eur J Pharmacol. 2009 Oct 12;620(1-3):42-8. doi: 10.1016/j.ejphar.2009.08.013. Epub 2009 Aug 15.

PMID:
19686730
4.

Opioids and motor complications in Parkinson's disease.

Samadi P, Bédard PJ, Rouillard C.

Trends Pharmacol Sci. 2006 Oct;27(10):512-7. Epub 2006 Sep 5.

PMID:
16908075
5.

Effect of ketanserin and amphetamine on nigrostriatal neurotransmission and reactive oxygen species in Parkinsonian rats. In vivo microdialysis study.

Nowak P, Szczerbak G, Biedka I, Drosik M, Kostrzewa RM, Brus R.

J Physiol Pharmacol. 2006 Dec;57(4):583-97.

6.

Acute L: -DOPA effect on hydroxyl radical- and DOPAC-levels in striatal microdialysates of parkinsonian rats.

Nowak P, Kostrzewa RA, Skaba D, Kostrzewa RM.

Neurotox Res. 2010 Apr;17(3):299-304. doi: 10.1007/s12640-009-9105-2. Epub 2009 Sep 4.

PMID:
19760476
7.

Adenosine A2A and dopamine receptor interactions in basal ganglia of dopamine denervated rats.

Carta AR, Pinna A, Tronci E, Morelli M.

Neurology. 2003 Dec 9;61(11 Suppl 6):S39-43.

PMID:
14663008
8.
9.

Impact of grafted serotonin and dopamine neurons on development of L-DOPA-induced dyskinesias in parkinsonian rats is determined by the extent of dopamine neuron degeneration.

Carlsson T, Carta M, Muñoz A, Mattsson B, Winkler C, Kirik D, Björklund A.

Brain. 2009 Feb;132(Pt 2):319-35. doi: 10.1093/brain/awn305. Epub 2008 Nov 27.

PMID:
19039008
10.

Enhanced striatal opioid receptor-mediated G-protein activation in L-DOPA-treated dyskinetic monkeys.

Chen L, Togasaki DM, Langston JW, Di Monte DA, Quik M.

Neuroscience. 2005;132(2):409-20.

PMID:
15802193
11.

Transplantation of autologous sympathetic neurons as a potential strategy to restore metabolic functions of the damaged nigrostriatal dopamine nerve terminals in Parkinson's disease.

Nakao N, Shintani-Mizushima A, Kakishita K, Itakura T.

Brain Res Rev. 2006 Sep;52(2):244-56. Epub 2006 Apr 27. Review.

PMID:
16644019
12.

[Development of dyskinesias induced by treatment for Parkinson's disease: potential role of first exposure to L-DOPA (or phenomenon of priming)].

Damier P, Tremblay L, Féger J, Hirsch EC.

Rev Neurol (Paris). 2000 Mar;156(3):224-35. Review. French.

PMID:
10740093
13.

Short review on dopamine agonists: insight into clinical and research studies relevant to Parkinson's disease.

Radad K, Gille G, Rausch WD.

Pharmacol Rep. 2005 Nov-Dec;57(6):701-12. Review.

14.

Chronic L-DOPA therapy alters central serotonergic function and L-DOPA-induced dopamine release in a region-dependent manner in a rat model of Parkinson's disease.

Navailles S, Bioulac B, Gross C, De Deurwaerdère P.

Neurobiol Dis. 2011 Feb;41(2):585-90. doi: 10.1016/j.nbd.2010.11.007. Epub 2010 Nov 16.

PMID:
21092759
15.
17.

Effect of adenosine A(2A) receptor antagonists on L-DOPA-induced hydroxyl radical formation in rat striatum.

Gołembiowska K, Dziubina A, Kowalska M, Kamińska K.

Neurotox Res. 2009 Feb;15(2):155-66. doi: 10.1007/s12640-009-9016-2. Epub 2009 Mar 5.

PMID:
19384578
18.

Neuroprotective effect of L-DOPA co-administered with the adenosine A2A receptor agonist CGS 21680 in an animal model of Parkinson's disease.

Agnati LF, Leo G, Vergoni AV, Martínez E, Hockemeyer J, Lluis C, Franco R, Fuxe K, Ferré S.

Brain Res Bull. 2004 Aug 30;64(2):155-64.

PMID:
15342103
19.
20.

Parkinson's disease--opportunities for novel therapeutics to reduce the problems of levodopa therapy.

Fox SH, Chuang R, Brotchie JM.

Prog Brain Res. 2008;172:479-94. doi: 10.1016/S0079-6123(08)00923-0. Review.

PMID:
18772047

Supplemental Content

Support Center